日本機械学会北海道支部

バイオメカニクス懇話会

第 36 回講演会（共催：日本機械学会北海道支部，日本機械学会バイオエンジニアリング部門「計測と力学-生体への応用-」研究会，日本生体医工学会専門別研究会「バイオメカニクス研究会」
）

主査

大橋俊朗

日

時：2019 年 7 月 4 日（木），16:00～17:30

場

所：北海道大学大学院工学研究院・工学部

大会議室 A1-17 室

http://www.eng.hokudai.ac.jp/building/?place=outer講

演：16:00～16:45「Complex Adaptive Cancer Immunotherapy」
Prof. In-San Kim, Korea Institute of Science and Technology (KIST)/Korea University, Korea
Immunotherapy is revolutionizing the treatment of cancer. The current
immunotherapeutics that work by taking the brakes off T cells have been particularlytransformational, dramatically improving outcomes for some cancer patients. But we stillneed to answer to those patients whose cancers do not respond to these immunotherapeutics,
and those whose cancers respond initially but then become resistant to the treatments.
The more we study the major issues of tumors, the more we come to realize that they cannot
be understood in isolation. Tumors are systemic problems, which mean that they areinterconnected and interdependent. Cancer cells are present within a complex adaptive
ecosystem consisted of associated cells including immune cells, connective tissue cells,
endothelial cells within a scaffold of matrix altogether forming tumor microenvironment.
Cancer, perhaps uniquely among human illnesses, is a disease that arises through Darwinian
interactions of microenvironmental selection and phenotypic adaptation, which are bothcauses and consequences of its complexity and heterogeneity.
Since a life has begun 3.5 billion years ago, they ensured continuous interaction between
the diverse species, both cooperative and fiercely competitive in nature. So they havedeveloped complex and sophisticated immune system to survive. Can we develop better systems
to fight against cancer than our own immune system? Even though we do not understandcompletely our own immune systems, we could try at least to awaken our own immune systemto fight against cancer. In an attempt to trigger our own immunity against cancers, we
utilized the characteristic of genetic instability to our advantage, as the expressionof cancer cell neoantigens triggers immunity against cancer cells, which can be called“intrinsic cancer vaccination”.
For this purpose, we designed protein nanocages or extracellular vesicles (exosomes),
which hold not only ligands for enhancing cancer cell phagocytosis but also drugs for
inducing immunogenic cancer cell death. This strategy will allow us to avoid using known
tumor specific antigens, ex vivo manipulation and adoptive cell therapy, instead,efficiently present neoantigens of cancer cells to our immune system. This strategy could
be combined with other treatment modalities to potentiate the therapeutic efficacy.

16:45～17:30「H-TRAIN : Hongreung Biomedical Cluster」
Prof. Kuiwon Choi, Korean Institute of Science and Technology (KIST), Korea
H-TRAIN Program is a translational research program developed in 2018.

The purposeof the program is to facilitate commercialization of the biomedical technologies developedin KIST. This program is originated from Translational Research Center (TRC) Program inKIST since 2012, then updated and renamed as H-TRAIN.
Hongreung is the area where the origin of Korean R&D since 1966 when KIST was developed.
KAIST has once also been located in this area, although KASIT moved to other city in late1980's. Around this area there exist more than 10 universities, 2 major university
hospitals, 2 specialized government hospitals and 3 government-sponsored research
institutes including KIST.
Approximately 5,000 ph.D.s are working in this area.
Recently, Seoul city developed the Seoul Bio-hub in this area to promoteindustrialization of biomedical technologies as an accelerating organization. For now,there are more than 30 start-ups are under incubation and more start-ups will beaccommodated soon.
In Korea, the biomedical area is now considered as one of main future growth engine
of Korean economy. Thus a lot of efforts both from the Government and local governments
has been put into this area. The role of GRIs becomes more emphasized and theindustrialization of the biomedical technologies is essential to the future of Korea. This
is why H-TRAIN was born in KIST.
In this presentation, I will introduce the H-TRAIN program along with the future ofHongreung Biomedcal Cluster.

問い合わせ先：大橋 俊朗

北海道大学大学院工学研究院人間機械システムデザイン部門

Tel&Fax: 011-706-6424, Email: ohashi@eng.hokudai.ac.jp